$AIDX News

20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026

20/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest™ Franchise Model

Healwell AI (TSX:AIDX) Stock Draws Fresh Price Target Split After Quarterly Results

20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity

20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity

20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level

20/20 Biolabs Q2 EPS $(0.26) Misses $(0.06) Estimate, Sales $730.571K Miss $891.000K Estimate

20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management’s Recent East Asia Business Development Tour

20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy

20/20 BioLabs Mulls Merger, Acquisition, Licensing, JV, Commercial Collaborations Across East Asia Under Its Roll-Up Strategy

20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock

BioLabs Announces Standstill Agreement With Streeterville Capital Regarding Outstanding Series E Convertible Preferred Stock, Effective July 16

20/20 BioLabs Highlights Investor Webinar Focused on OneTest™ for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth

Healwell AI (TSX:AIDX) Stock Fair Value Falls As Analysts Trim Growth Assumptions

20/20 BioLabs Announces Monthly Investor Webinar Series to be Held on the First Wednesday of Each Month

20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters

20/20 Biolabs' OneTest Multi-Cancer Early Detection Blood Test Selected As Part Of Firefighter Cancer Screening Initiative For State Of Vermont In Partnership With National Diagnostic Services

20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand

20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress

20/20 Biolabs Q1 EPS $(0.28) Misses $(0.10) Estimate, Sales $353.375K Miss $779.000K Estimate